key: cord-0808442-8kezr83s
authors: Jacofsky, David; Jacofsky, Emilia M.; Jacofsky, Marc
title: Understanding Antibody Testing for COVID-19
date: 2020-04-27
journal: J Arthroplasty
DOI: 10.1016/j.arth.2020.04.055
sha: 6ab2f323dbac8268462f9f755207201c1ecf2539
doc_id: 808442
cord_uid: 8kezr83s

The orthopedic community has seen the COVID-19 pandemic decimate elective surgical volumes in most geographies. Patients and essential workers, such as health care providers, remain rightfully concerned about how to appropriately begin to return to work and community activity in a safe and responsible manner. Many believe that testing for the presence of antibodies on a widespread scale could help drive evidence-based decision-making, both on an individual and societal scale. Much information, and an equal amount of misinformation, has been produced on antibody testing. Education about the role and science of such testing is critically important for programs to be effectively understood and managed.

16

The orthopaedic community has seen a pandemic decimate elective surgical volumes in most 17

geographies. Patients and essential workers, such as healthcare providers, remain rightfully concerned 18 about how to appropriately begin to return to work and community activity in a safe and responsible 19

manner. Perhaps screening all staff and testing all preoperative elective patients for the presence of 20 virus through molecular testing would help minimize a second spike in disease. Many believe that 21 testing for the presence of antibodies on a widespread scale could help drive evidence-based decision 22

making, both on an individual and societal scale. Much information, and an equal amount of 23 misinformation, has been produced on antibody testing. We believe that there is real value in such 24 immune response testing, but also know that education about the role and science of such testing is 25 critically important for programs to be effectively understood and managed. 26 27

On December 31, 2019, twenty seven (27) cases of pneumonia of unknown etiology were identified in 28 Wuhan City, Hubei province in China (Lu, Stratton, & Tang, 2020) (Abul K Abbas & Pillai, 2016). The 29 causative agent was ultimately identified from throat swab samples conducted by the Chinese Center 30

for Disease Control and Prevention (CCDC) in January 2020 and was subsequently named Severe Acute 31

Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The disease name was simplified to COVID-19 by the 32

World Health Organization (WHO) (Davis, 2013) . To date, many COVID-19 positive patients have 33

developed mild symptoms such as dry cough, sore throat, and fever. The majority of cases have 34 spontaneously resolved, and many infected patients have proven to be completely asymptomatic. 35 However, some have developed various fatal complications including organ failure, septic shock, 36 pulmonary edema, severe pneumonia, and atypical Acute Respiratory Distress Syndrome (ARDS) 37 (Nicholson, 2016 ) (Chen et al., 2020) (Wang et al., 2020) . Typically, patients who require intensive care 38 support were older and had multiple comorbidities including cardiovascular, cerebrovascular, endocrine, 39 digestive, and respiratory disease (Sohrabi et al., 2020) . 40 41

There are currently few studies that define the pathophysiological characteristics of COVID-19, and 42

there is great uncertainty regarding its mechanism of spread. Current knowledge is largely derived from 43 similar coronaviruses, which are transmitted from human-to-human through respiratory fomites ("How 44

Coronavirus Spreads | CDC," n.d.). Typically, respiratory viruses are most contagious when a patient is 45 symptomatic. However, there is an increasing body of evidence to suggest that human-to-human 46 transmission may be occurring during the asymptomatic incubation period of COVID-19, which has been 47 estimated to be between 2 and 10 days ("How Coronavirus Spreads | CDC," n.d.) ( for physicians to understand that most marketed products in this category today still require a Clinical 96

Laboratory Improvement Amendments (CLIA) lab certification for moderate or high complexity tests to 97 be performed, and despite their simplicity can't be done in a typical private office (CDRH; FDA, 2020). 98

The details of the EUA process and its implications is outside the scope of this manuscript and is rapidly 99 changing. However, the FDA guidance is easy to find online with real time updates. 100 By helping to detect the immunity of an exposed population, monitor the spread of disease, test the 101 infection status of a workforce segment, and study the disease's progression, data can be used to make 102 educated decisions about quarantine and social distancing regionally or locally and can be used to risk 103 stratify healthcare providers, police, firefighters, utility workers, and other essential workforce 104 employees. Testing also may provide peace of mind to surgeons who are unsure if they have been 105 exposed to the virus, or if they ever developed immunity to the virus. Knowing these facts may educate 106 decisions about the need for personal protective equipment and one's willingness to work with COVID-107 19 positive patients in the elective setting. 108 109 Antibody Function 110 An antibody, also called an immunoglobulin, is a protective protein produced by the immune system in 111 response to the presence of a foreign substance (antigen), such as a pathogen. Antibodies recognize and 112 latch onto antigens in order to remove them from the body. Antibodies are proteins produced and 113 secreted by B cells (lymphocytes) (Murphy, 2012) . 114

Because a principal function of B lymphocytes is antibody production, it is important to understand the 115 salient features of these defense molecules and describe their different isotypes or classes. Antibodies 116 are glycosylated protein molecules present on the surface of B cells (surface immunoglobulins) serving 117 as antigen receptors (BCR) or are secreted into the extracellular space where they can bind and 118 neutralize their target antigens (Murphy, 2012) . A single antibody molecule consists of four protein 119 chains: two "heavy" (H chains) and two "light" (L chains) linked to each other by disulfide bonds. The N-120 terminus regions of the heavy and light chains, which collectively make up the antigen-binding site, are 121

where the variability between one antibody molecule and another resides, hence determining 122

specificity. An important feature is that each antibody recognizes a specific antigen, a phenomenon 123 called "antibody specificity." For example, an antibody that recognizes the mumps virus cannot 124 recognize the measles virus and can only recognize one particular binding site on the mumps virus. 125

There will likely be multiple antibodies to multiple different binding sites on an antigen such as a virus. 126

For example, some antibodies to COVID-19 will target binding sites on proteins in the outer shell while 127 some may target nucleic acid binding sites, but each will be specific and unique. Only when two 128 different, but similar, viruses have identical structures will cross-reactivity occur. For example, if 129 multiple strains of a coronavirus have maintained regions of nucleic acid that have not undergone 130 mutation, an antibody that targets that region in one may target the identical region in another. 131

Conversely, an antibody that recognizes the measles virus generally cannot recognize the mumps virus. 132

Five isotypes, or classes, of antibodies (IgM, IgD, IgG, IgA, and IgE) exist, and they are distinguished 133

according to the C-terminus regions of the heavy chains, which are constant and therefore do not 134 participate in antigen binding. Instead, these regions (designated Fc) are important for the common 135 effector functions of antibodies, the means by which antibodies eliminate pathogens or alternatively 136

cause tissue injury. It should be noted that there are four subclasses or isotypes of IgG antibodies (IgG1,  137 IgG2, IgG3, and IgG4), the distinction of which is beyond the scope of this discussion. Antibodies exert 138 effector functions in three principal ways (Murphy, 2012) : 139

Antibodies are found in plasma and in extracellular fluid. Antibodies have three primary functions. 140 1) Antibodies are secreted into the blood and mucosa, where they bind to and inactivate foreign 141 substances such as pathogens and toxins (neutralization). Antibody neutralization is important 142

for protection from viruses, as it can prevent the virus from then being able to enter and infect 143 cells. It is also important in binding to bacterial toxins and is the primary mechanism for 144 protection conferred by successful vaccination. 145

2) Antibodies facilitate phagocytosis of foreign substances by phagocytic cells (opsonization). 146 Antibody binding, for example, will not prevent bacterial replication. Rather, in this setting, the 147 mechanism of enhanced protection through opsonization will increase phagocytosis by 148 macrophages and neutrophils. 149

3) The third function is antibody activation of the complement system to destroy pathogens 150 through lysis and enhanced chemotaxis. 151

After an infection, the cells producing pathogen-specific antibodies multiply and increase proportionally. 153

As a result, the body is protected from repeated infection. This feature is called "immunological 154 memory." One of the most significant features of the immune response is its ability to retain a memory 155 of previous infections, and this is also the principal behind the effectiveness of vaccinations. This both 156 protects individuals from reinfection and limits the spread of infection in a community. Immune 157 memory can be very long-lasting; immunological memory for the measles infection in adults decays so 158 slowly, it would take over 3,000 years to decrease by half. This therefore goes well beyond life-long 159 protection for this particular antigen. These robust durable changes are the reason that, when we 160 vaccinate, the protection this produces delivers long-term benefits. Within an individual, immune 161 memory must be distributed throughout the body. Circulating antibodies travel in the blood, reaching 162 everywhere the circulation does including extracellular spaces and in secretions. Natural killer (NK) cells 163

can remain on guard within tissues "alert" but not activated, ready to attack rapidly if reinfection occurs. 164 NK cells are activated in response to macrophage-derived cytokines and they serve to contain viral 165 infections while the adaptive immune response generates antigen-specific cytotoxic T cells that can clear 166 the infection. NK cells work to control viral infections by secreting interferon gamma and TNFα while 167 also stimulating NK cells nearby with such secretions and destroying physiologically challenged cells due 168

to viral infection or malignancy through complex mechanisms outside the scope of this review. 169

Finally, some infections have such a profound impact on a species that the imprint of individual 170 pathogens can be seen in the tree of evolution. If an infection is lethal, only individuals who have genes 171 that encode effective resistance will survive to produce the next generation, thereby driving herd 172 immunity through natural selection rather than vaccination or infection. With the rapid acceleration of the COVID-19 pandemic there has been a rush to develop tests that can 237 detect the presence of antibodies produced by the body in response to exposure/infection with the 238 SARS-CoV-2 virus. These testing methodologies rely on the antigen-antibody binding affinity described 239

above. The test principle relies on a recombinant antigen produced in the laboratory which is designed 240

to mimic specific structures of the virus, causing any antibodies present in whole blood or serum with a 241 binding affinity to attach to the antigen. The specificity of the test can be highly dependent upon the 242 target antigen that is chosen as some viral structures can be highly conserved across broad families of 243 virus and others can be highly derived and specific to a given strain. Therefore, it is important to 244

understand the cross reactivity to other viruses of the test being used so as to avoid misinterpretation of 245 a false positive result that may be detecting an antigen from a similar virus, yet not confer immunity to 246 the SARS-CoV-2 virus. These tests fall into two broad categories: laboratory-based immunoassays which 247 require a reader or analyzer to detect the reaction, and cassette-based systems which can be read at the 248 point of care through a change in color in an indicator region visible to the naked eye. 249

Laboratory-based immunoassays have several technical advantages when compared to cassette-based 250 systems. Because they are read by sensitive laboratory instrumentation and a controlled aliquot is 251 delivered to the test system, they can be considered quantitative or semi-quantitative tests. Therefore, 252 they can determine how much of a given antibody (titer level) is present per unit volume of serum and, 253

when operating at the margins of detection, their sensitivity and specificity can be higher than cassette-254 based systems. However, these systems have real disadvantages. Infrastructure costs, requirements for 255 venous puncture, additional steps in sample processing, time to obtain results, and practical through put 256 challenges are problematic and substantially increase cost per test. 257

Cassette-based systems rely on a color change that is visible to the human eye and is more appropriate 258

for use at the point of care with almost immediate results available to healthcare workers and patients. 259

Cassette systems use the principle of lateral flow immunoassay or immunochromatography. The 260

cassette contains a shallow well into which approximately 10 to 15ul (e.g. two small drops from a finger 261 prick) of whole blood, serum or plasma are placed along with a small quantity of buffer specific to the 262 test kit. The blood and buffer are absorbed into a porous test strip which is impregnated with 263 recombinant viral antigens doped with an indicator (e.g. colloidal gold, latex particles, europium, or 264 quantum dots). Antibodies from the serum bind to antigens in the test strip and are wicked laterally 265 along the length of the test strip. In the indicator regions of the test kit, anti-human antibodies which 266

are immobilized in the test strip will bind to the antigen-antibody complex and hold them in the 267 indicator region. The colloidal gold, or other colorant, accumulates in the indicator region leading to a 268 visible change in color along a narrow band of the wicking substrate. There may be one or more 269

indicator regions with anti-human antibodies that are specific to IgM, IgG or other immunoglobulins. All 270 tests should also contain a "Control" indicator line to confirm that the test sample has appropriately 271 wicked along the length of the assay and antigens in the test kit remain viable, therefore confirming a 272 valid test procedure (Figure 1 ). This entire process, from finger-stick to result, occurs in less than 15 273 minutes. 274

These points of care test cassettes are intended to be read as a binary outcome (presence/absence) for 275 each antibody indicator region. While the degree of color change may be an indicator of the quantity of 276 antibody present in a sample, variability between antibody concentrations in whole blood, plasma and 277 serum along with a buffer that is added in "drops" make it unreliable to attempt interpretation of color to 7 days after the initial onset of symptoms (assuming a patient does develop symptoms after infection. 307

The IgM then remains above the detection threshold for 14 to 21 days from symptom onset. About 308 midway through the rise and fall of IgM production, around day 14 post-symptom onset, IgG will rise 309 above detection levels. IgG production will generally continue to rise for 28 to 35 post symptom onset, 310

peaking around or after clinical recovery. IgG typically has a long half-life and will remain above 311 detectable thresholds for months or even years after the resolution of infection. 312

The clinical level of functional immunity imparted by SARS-CoV-2 IgG antibodies, and their critical 313 concentration cutoffs, have not been determined for this virus. Therefore, recommendations must be 314 based on similar viruses and knowledge of the immune system. Ultimately, this information will be 315 available and quantitative tests will be valuable in determining immunity titers months and years after 316 COVID-19 infection or vaccination, once vaccines exist. Based on experience with other viruses, if 317 reinfection does occur with the same pathogen one would expect symptom severity and duration to be 318 greatly reduced due to the inherent memory of the immune system. Further, the hyperimmune 319 response that leads to ARDS and which is associated with the high mortality rate of this virus would 320 expect to be mitigated by the presence of a prior immune response. 321

For the interpretation of results in an effort to make meaningful recommendations on community 322 behavior to test recipients, there are several factors that must be considered: This result does not rule out that the subject was recently exposed to the virus and is not yet producing 332 antibodies. A subject that was recently exposed to the virus could spread the disease even if this test is 333 negative and they are asymptomatic. As long as the virus is spreading in the community, the subject 334 should continue to practice social distancing or current guidelines to protect themselves and those 335 around them. If the subject does develop symptoms, they should seek medical care and repeat testing 336 based on future potential exposure or symptoms. 337

IgG is positive and IgM is negative (Figure 2) : The subject's immune system has produced longer acting 338

antibodies to the target viral antigen. Subject likely had the infection several weeks ago, even if no 339 symptoms were present. The subject has some degree of functional immunity to the virus. Depending 340 upon the time that has passed since exposure, it is unlikely that the subject is spreading virus. A 341 molecular test may be used to rule out viral shedding (as discussed in greater detail in the next section). 342

IgM is positive and IgG is negative (Figure 3 ): This test result indicates that the immune system is 343

actively producing antibodies to a recent infection. The subject should immediately isolate from healthy 344 individuals and seek further medical advice if symptoms develop. This subject can likely spread disease 345 to others, even when asymptomatic. Subject may remain symptom free, experience minor symptoms or 346

worsening symptoms as the disease course progresses. Subject should be vigilant and seek care 347 appropriate to the symptoms they experience. After at least 14 to 21 days, the subject should consider 348

repeat testing to confirm their IgG antibody status has become positive and they are outside the 349 expected window to shed virus before returning to normal activities. If more rapid return to community 350 activities is warranted, e.g. for critical industry workers, a molecular test should be performed to assess 351 viral shedding status. 352

Both IgM and IgG are positive (Figure 4 ): Subject's immune system is actively producing antibodies to an 353 ongoing infection that likely began more than 14 days ago. Subject should immediate isolate from 354 healthy individuals and seek further medical advice if symptoms develop. Subject is likely experiencing 355 an asymptomatic disease course but may still be able to spread the disease to others. Consider repeat 356 testing in 7 to 14 days to confirm IgG only status before returning to normal activities. If more rapid 357 return to community activities is warranted, e.g. for critical industry workers, a molecular test should be 358 performed to assess viral shedding status. 359

Interpreting results when Symptomatic at the time of testing: 360

Both IgM and IgG are negative: Subject's immune system has not produced any antibodies to the target 361 viral antigen. If it has been greater than 7 days since onset of fever or other symptoms, the disease is 362 unlikely to be COVID-19, but a full panel test including COVID-19, influenza and bacterial bronchitis 363 could be performed if available and recommended based on history and symptoms. If it has been less 364 than 7 days since the onset of symptoms, COVID-19 cannot be ruled out with antibody testing alone. status before returning to normal activities. If more rapid return to community activities is warranted, 388 e.g. for critical industry workers, a molecular test should be performed to assess viral shedding status. 389

As outlined above, regardless of the testing methodology employed to detect antibodies, these tests are 390 not intended to be used a means to diagnose an active infection. This is primarily because 1) there is a 391 temporal lag between exposure to the virus and the development of antibodies by the immune system 392 and 2) antibodies will persist long after the body has cleared an infection. These tests are an excellent 393 tool to be used in parallel with molecular testing, patient history and clinical presentation in 394 symptomatic patients or used in asymptomatic patients over a period of time to understand return to 395 activity recommendations. The temporal framework related to exposure, onset of symptoms, 396 production of IgM and IgG, symptom resolution and virus shedding throughout the course of disease 397

have not been well quantified for SARS-CoV-2 specifically. At this time, most of the data and 398

recommendations have been extrapolated from the studies done on the first SARS outbreak in the early 399 21st century. It is also important to understand, that molecular testing is imperfect as well, with up to 400 30% false negative rates in some series. Therefore, when looking at the sensitivity and specificity of 401 antibody testing, one must be academic enough to recognize the inherent weaknesses of using such a 402 test to evaluate another test. It will be hard to know whether a positive antibody test in a patient with a 403 negative molecular test means the former test is a false positive or the latter was a false negative. 404

Physicians must truly diligence these products and be satisfied with the data, as well as the track record 405 of the company marketing it. We expect a lot more information to be forthcoming in the peer-reviewed 406 literature over the next 6 to 18 months which will improve the interpretation and utility of antibody 407

tests. 408 409 Long-Term Immunity -Does it Exist with COVID-19? 410

A study in the wake of SARS, the similar coronavirus that triggered an epidemic in 2003, showed that 411 survivors maintained neutralizing antibodies for two years on average, with the number of antibodies 412 declining thereafter. Other coronaviruses in circulation in the human species also lead to at least partial 413 immunity for some period of time . The immunity question has implications for whether COVID-19  414  follows an annual cycle like seasonal influenza or becomes dormant for multiple years and then erupts  415 again, according to a recent publication in the journal Science. The authors noted that two other 416 coronaviruses in circulation (OC43 and HKU1), which cause common colds, result in about 45 weeks of 417 immunity on average. If the new virus follows that pattern, it would probably create annual outbreaks, 418 they found (Kissler, Tedijanto, Goldstein, Grad, & Lipsitch, 2020). However, generally speaking, the 419 sicker you become due to an infection and the robust immune system response to it, the more robust 420 the immunity provided. Therefore, one might assume that those people who get the most ill have the 421 longest and most effective immunity after a re-exposure to the same virus. In a study by Callow antibody titers were positively correlated with plasma CRP levels but negatively correlated with the 438 lymphocyte counts of patients at the time of admission, indicating an association between degree of 439 humoral response and cellular immune response. However, those with mild disease who do not 440

develop high levels of antibodies may be at increased risk of re-infection, but are not likely to get 441 significant symptoms, although the may be contagious. Therefore, those without antibody production 442

should likely be treated as if they never had the disease from a social distancing perspective, even if they 443 were proven to be positive with molecular testing .  444  445  Conclusion  446  447 Longitudinal serological studies are urgently needed to determine the extent and duration of immunity 448

to SARS-CoV-2. It will undoubtedly take time for this data to become available. Despite the hyperbolic 449 media coverage regarding antibody testing, initially positive, and then a week later somewhat negative, 450 physicians must continue to do what we have always done. We must accept that data, especially early 451 data, is rarely complete or perfect and we must utilize the existing body of knowledge to make 452 evidence-based decisions. We believe that there exists a real value in antibody testing when performed 453

properly with quality devices and a good understanding of how to interpret the clinical meaning of the 454 results. Such testing can help educate decisions regarding social distancing and the use of personal 455 protective equipment and can help risk stratify essential work force members. As physicians we know 456 that there is no "perfect" test, and it behooves us all to make certain that we utilize as many data points 457 as possible while trying to safely recover from both this pandemic and the possible secondary spikes in 458

COVID-19 incidence that may appear prior to widespread vaccination. 459 460 461 The typical lateral flow immunoassay cassette with a control band "C" and two antibody 543 indicators. The "M" band indicates the presence of IgM and "G" band indicates IgG is detected.

For a test to be considered valid the control band must be present. Therefore, the test cassette on 545 the left would be considered a negative test result (Control band and no antibody bands) while 546 the cassette on the right would be an invalid result (lack of control band, despite both antibody 547 bands being present). 

Outbreak of pneumonia of unknown etiology in 464

The mystery and the miracle

Basic Immunology: Functions and Disorders of the 467

The Compatibility Gene. Penguin Books Limited

The immune system

Epidemiological and clinical 472 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, 473 China: a descriptive study

Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia

World Health 480 Organization declares global emergency: A review of the 2019 novel coronavirus 481 (COVID-19)

How Coronavirus Spreads | CDC n

Transmission of 2019-NCOV infection from an asymptomatic contact in Germany

Early Transmission Dynamics 488 in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Coronavirus Cases

World Heal Organ 493 n

Proclamation on Suspension of Entry as Immigrants and Nonimmigrants of 496 Persons who Pose a Risk of Transmitting 2019 Novel Coronavirus | The White 497

Primerdesign launches new molecular test for novel coronavirus n.d

Contains Nonbinding Recommendations This document supersedes 507 "Policy for Diagnostics Testing in Laboratories Certified to Perform High-508

Complexity Testing under Clinical Laboratory Improvement Amendments (CLIA) 509 prior to Emergency Use Preface Public Comment

Janeway's Immunobiology

Development and Clinical Application 512 of A Rapid IgM IgG Combined Antibody Test for SARS CoV 2 Infection 513

Neutralizing antibody 515 responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their 516 implications

CoV-2 in patients of novel coronavirus disease 2019

Projecting the 521 transmission dynamics of SARS-CoV-2 through the post-pandemic period

MedRxiv 2020

The time course of the immune 524 response to experimental coronavirus infection of man

The reproductive number of COVID-527 19 is higher compared to SARS coronavirus